-
Press ReleaseTest New ROOT Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis to launch Direct-to-Patient platform for Cosentyx® (secukinumab) in the US
-
Press ReleaseNovartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease
-
Press ReleaseNovartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
-
Press ReleaseNovartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
-
Press ReleaseFDA approves Novartis radioligand therapy Pluvicto® for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant prostate cancer
-
Press ReleaseNew Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA
-
Press ReleaseNovartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
-
Press ReleaseNovartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
-
Press ReleaseNovartis Entresto® US patent upheld by US Court of Appeals
-
Press ReleaseLonger-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer